Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up.
Simon JavidiAli DiraniFares AntakiMarc SaabSofiane RahaliGhassan CordahiPublished in: Journal of ophthalmology (2020)
This retrospective study of 180 nAMD patients treated with a TER of intravitreal anti-VEGF demonstrates an initial improvement of BCVA after loading phase, followed by long-term visual stabilization for at least six years. These results were obtained with a high number of injections, averaging close to six injections per year during long-term follow-up. In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used.
Keyphrases
- age related macular degeneration
- growth factor
- vascular endothelial growth factor
- endothelial cells
- ejection fraction
- newly diagnosed
- optical coherence tomography
- ultrasound guided
- platelet rich plasma
- prognostic factors
- electronic health record
- machine learning
- metabolic syndrome
- type diabetes
- skeletal muscle
- patient reported outcomes
- artificial intelligence